Literature DB >> 15909203

Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis.

Varinder Kumar1, N k Ganguly, Kusum Joshi, Rahul Mittal, Kusum Harjai, Sanjay Chhibber, Saroj Sharma.   

Abstract

In the present study, protective efficacy of Escherichia coli capsular antigen, K13, was evaluated in a mouse model of pyelonephritis. Unconjugated capsular polysaccharide failed to provide any protection. However, coupling of K13 to diphtheria toxoid (DT) enhanced its immunogenicity and led to significant production of anticapsular antibodies in mice. Immunization of animals with K13-DT conjugate also caused significant improvement in cell-mediated immune response as indicated by an increase in lymphoblastogenic response and in the CD4+/CD8+ cell ratio of splenic lymphocytes. Significant decrease in bacterial load and renal severity scores were observed in K13-DT immunized animals. Suitability of K13-DT conjugate as an effective vaccine candidate against urinary tract infections caused by E. coli has been discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909203     DOI: 10.1007/s00430-005-0241-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  38 in total

1.  Role of bacterial virulence factors and host factors in the outcome of Escherichia coli bacteraemia.

Authors:  T A Hekker; A B Groeneveld; A M Simoons-Smit; P de Man; H Connell; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-04       Impact factor: 3.267

Review 2.  Capsular polysaccharides and their role in virulence.

Authors:  Clare M Taylor; Ian S Roberts
Journal:  Contrib Microbiol       Date:  2005

3.  Occurrence and characterisation of uropathogenic Escherichia coli in urinary tract infections.

Authors:  R Raksha; H Srinivasa; R S Macaden
Journal:  Indian J Med Microbiol       Date:  2003 Apr-Jun       Impact factor: 0.985

4.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis.

Authors:  B Kaijser; P Larsson; W Nimmich; T Söderström
Journal:  Prog Allergy       Date:  1983

6.  Cell-mediated immune parameters in children with pyelonephritis caused by Escherichia coli.

Authors:  S Ahlstedt; M Hagberg; U Jodal; S Mårild
Journal:  Prog Allergy       Date:  1983

7.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

Review 8.  Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines.

Authors:  W T M Jansen; Harm Snippe
Journal:  Indian J Med Res       Date:  2004-05       Impact factor: 2.375

Review 9.  Conjugate vaccines.

Authors:  Stephen Lockhart
Journal:  Expert Rev Vaccines       Date:  2003-10       Impact factor: 5.217

10.  The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales.

Authors:  Alessia Melegaro; W John Edmunds
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

View more
  5 in total

Review 1.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

Review 2.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

3.  Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development.

Authors:  Yongqun He; Zuoshuang Xiang; Harry L T Mobley
Journal:  J Biomed Biotechnol       Date:  2010-07-04

Review 4.  Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections.

Authors:  Paul Loubet; Jérémy Ranfaing; Aurélien Dinh; Catherine Dunyach-Remy; Louis Bernard; Franck Bruyère; Jean-Philippe Lavigne; Albert Sotto
Journal:  Front Microbiol       Date:  2020-07-03       Impact factor: 5.640

5.  Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Authors:  Christopher J Alteri; Erin C Hagan; Kelsey E Sivick; Sara N Smith; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.